Financials
Financial year 2025
Remopharma from Sint-Gillis-Waas, company number BE0806560542, closed financial year 2025 with a result of € 241,142 after tax. For that financial year Remopharma recorded a gross margin of € 1.1 million and equity of € 2.2 million. Compared with financial year 2024, the result moved from € 295,595 to € 241,142. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 18, 2026.
€ 2.2 million
▲ 12% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 241,142
▼ 18% vs 2024
Profit after tax over the fiscal year.
€ 233,124
▲ 20% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 2.2 million.
People and assets in 2025
7
▲ 0.9 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 455,871
▲ 38% vs 2024
€ 65,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 16,562
▼ 9% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 754,104
▼ 11% vs 2024
€ 124,793 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.
€ 628,904
▲ 41% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 73,891
▲ 50% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € 932,226 | € 965,347 | € 1,102,250 | ▲ 14% |
| Profit after taxes | € 304,120 | € 295,595 | € 241,142 | ▼ 18% |
| Equity | € 1,668,423 | € 1,964,018 | € 2,205,160 | ▲ 12% |
| Total debts | € 1,582,385 | € 1,347,529 | € 1,458,273 | ▲ 8% |
| Cash | € 252,574 | € 194,009 | € 233,124 | ▲ 20% |
| Land & buildings | € 1,192,673 | € 1,128,351 | € 1,162,576 | ▲ 3% |
| Retained profit | € 1,667,423 | € 1,963,018 | € 2,204,160 | ▲ 12% |
| Bank debt | € 981,638 | € 848,900 | € 754,104 | ▼ 11% |
| Balance sheet total | € 3,250,808 | € 3,311,547 | € 3,663,433 | ▲ 11% |
| Employees (FTE) | 5.3 | 6.1 | 7 | ▲ 0.9 |
Key figures of Remopharma, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Remopharma?
What happened at Remopharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 241,142 (▼ 18% vs 2024). filed late Source: NBB ↗
- New establishment in Sint-Gillis-Waas. KBO
- New establishment in Beveren-Kruibeke-Zwijndrecht. KBO
- Pieter Leys became a director. NBB
- New establishment in Sint-Niklaas. KBO
- New establishment in Beveren-Kruibeke-Zwijndrecht. KBO
- New establishment in Sint-Gillis-Waas. KBO
- Start of the company according to the CBE. KBO
In short
From € 304,120 profit in 2023 to € 241,142 profit in 2025.
Paid € 270,562 in corporate taxes since 2023.
Best year ever: 2023, with € 304,120 profit.
On average € 157,500 of value added per employee in 2025.
A new publication or filing at Remopharma? We notify you, reason included.
Follow RemopharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Remopharma are Christel Van Remoortel and Pieter Leys.
Directors
According to the 2025 annual accounts
Christel Van Remoortel
Statutaire Bestuurder
since 2008
Pieter Leys
Statutaire Bestuurder
since 2021
Establishments
Establishment units
Physical locations of this company
Meerdonkdorp(MD) 24
9170 Sint-Gillis-Waas
Hoog-Kallostraat(KAL) 22A
9120 Beveren-Kruibeke-Zwijndrecht
Active since 1 January 2011
Marktstraat 23
9111 Sint-Niklaas
Active since 23 December 2018
Kieldrechtsebaan(VER) 6A
9130 Beveren-Kruibeke-Zwijndrecht
Active since 31 December 2021
Sint-Gillisstraat(DKL) 16
9170 Sint-Gillis-Waas
Active since 19 March 2026
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Self-hosted
Hosting
CLOUDFLARENET - Cloudflare, Inc., US
DNS
Cloudflare DNS
Website info
Features
Security
Network
Details
- Company number
- 0806.560.542
- VAT number
- BE 0806.560.542
- Registered office
- Meerdonkdorp(MD) 24, 9170 Sint-Gillis-Waas
- Names & denominations
- Remopharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 24 September 2008
- Peppol
- Active · Active since 27 Sept 2024
- Contact
- remopharma.be
- Activities · NACE
Detailhandel in farmaceutische producten